Narrow your search
Listing 1 - 10 of 308 << page
of 31
>>
Sort by

Book
Use of naltrexone in low doses beyond the approved indication
Author:
Year: 2015 Publisher: Oslo : Norwegian Knowledge Centre for the Health Services (Nasjonalt kunnskapssenter for helsetjenesten),

Loading...
Export citation

Choose an application

Bookmark

Abstract

In Norway, naltrexone is approved as supportive treatment of alcohol dependence. The recommended dose is 50 mg, equivalent to the marketed tablet. Naltrexone in much lower doses than 50 mg has been used in Norway for the treatment of a variety of diseases, such as multiple sclerosis (MS), Crohn's disease, fibromyalgia, cancer, inflammatory bowel disease, chronic fatigue syndrome, and amyotrophic lateral sclerosis. Doses of 3 to 5 mg per day have often been termed low dose naltrexone. This use is beyond the approved indication. The purpose of this report is to examine whether there is a documented effect of the use of naltrexone in low doses. We summarized data from a systematic review and several randomized controlled and prospective controlled studies in order to investigate the effect of using naltrexone in low doses on illness, and on functioning in daily life and to examine the risk of side effects. We identified studies for people with:1. Crohn's disease (one systematic review, two studies) 2. multiple sclerosis (two studies) 3. fibromyalgia (two studies) 4. cancer (one study) 5. HIV (one study) 6. various pain conditions (three studies) 7. opioid dependence (six studies) All studies were either small, of short duration, or had other methodological limitations. We considered the documentation to have very low quality. That means that we cannot conclude whether the use of naltrexone in low doses is effective or safe.


Periodical
LiverTox : clinical and research information on drug-induced liver injury
Author:
Year: 2012 Publisher: Bethesda, MD : National Institute of Diabetes and Digestive and Kidney Diseases,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Periodical
LiverTox : clinical and research information on drug-induced liver injury
Author:
Year: 2012 Publisher: Bethesda, MD : National Institute of Diabetes and Digestive and Kidney Diseases,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Use of naltrexone in low doses beyond the approved indication
Author:
Year: 2015 Publisher: Oslo : Norwegian Knowledge Centre for the Health Services (Nasjonalt kunnskapssenter for helsetjenesten),

Loading...
Export citation

Choose an application

Bookmark

Abstract

In Norway, naltrexone is approved as supportive treatment of alcohol dependence. The recommended dose is 50 mg, equivalent to the marketed tablet. Naltrexone in much lower doses than 50 mg has been used in Norway for the treatment of a variety of diseases, such as multiple sclerosis (MS), Crohn's disease, fibromyalgia, cancer, inflammatory bowel disease, chronic fatigue syndrome, and amyotrophic lateral sclerosis. Doses of 3 to 5 mg per day have often been termed low dose naltrexone. This use is beyond the approved indication. The purpose of this report is to examine whether there is a documented effect of the use of naltrexone in low doses. We summarized data from a systematic review and several randomized controlled and prospective controlled studies in order to investigate the effect of using naltrexone in low doses on illness, and on functioning in daily life and to examine the risk of side effects. We identified studies for people with:1. Crohn's disease (one systematic review, two studies) 2. multiple sclerosis (two studies) 3. fibromyalgia (two studies) 4. cancer (one study) 5. HIV (one study) 6. various pain conditions (three studies) 7. opioid dependence (six studies) All studies were either small, of short duration, or had other methodological limitations. We considered the documentation to have very low quality. That means that we cannot conclude whether the use of naltrexone in low doses is effective or safe.

Dose-response relationships in clinical pharmacology. 3 : proceedings of the esteve foundation symposium III. Dose-response relationships in man, Son Vida, Mallorca, 13-15 october 1988
Authors: --- ---
ISBN: 0444810846 Year: 1989 Volume: vol 808 Publisher: Amsterdam : Excerpta medica,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
A Pharmacology Primer : Techniques for More Effective and Strategic Drug Discovery
Author:
ISBN: 0128139587 0128139579 9780128139585 9780128139578 Year: 2019 Publisher: London, England : Academic Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract

The dose-response relation in pharmacology.
Authors: ---
ISBN: 0387904158 Year: 1979 Publisher: New York (N.Y.) : Springer,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
2-Butoxyethanol
Author:
ISBN: 9241530103 Year: 1998

Loading...
Export citation

Choose an application

Bookmark

Abstract


Periodical
Dose-response : a publication of International Hormesis Society.
Authors: ---
Year: 2005 Publisher: Amherst, MA : Thousand Oaks, CA : International Hormesis Society, SAGE

Loading...
Export citation

Choose an application

Bookmark

Abstract

Health risks from exposure to low levels of ionizing radiation : BEIR VII phase 2.
Author:
ISBN: 1280447176 9786610447176 0309530407 9780309530408 030909156X 9780309091565 Year: 2006 Publisher: Washington National academies press

Listing 1 - 10 of 308 << page
of 31
>>
Sort by